estrogen-progestogen contraceptive carcinogenicity, IARC monograph hormones, combined oral contraceptive cancer, menopausal hormone therapy cancer, WHO cancer classification hormones, carcinogenic risk assessment, breast cancer hormone exposure, cervical cancer OC, endometrial cancer hormone therapy, ovarian cancer hormonal protection
PMID 18756632 18756632
Cite this article
International Agency for Research on Cancer (n.d.). *Combined Estrogen-Progestogen Contraceptives and Combined Estrogen-Progestogen Menopausal Therapy (IARC Monograph Vol 91)*.
International Agency for Research on Cancer. Combined Estrogen-Progestogen Contraceptives and Combined Estrogen-Progestogen Menopausal Therapy (IARC Monograph Vol 91).
International Agency for Research on Cancer. *Combined Estrogen-Progestogen Contraceptives and Combined Estrogen-Progestogen Menopausal Therapy (IARC Monograph Vol 91)*.
A tubo-ovarian abscess (TOA) is a complication of pelvic inflammatory disease (PID) resulting from an ascending infection of the upper genital tract. It is characterized by an inflammatory mass involv...
Salari N et al., 2023Journal of diabetes and metabolic disorders
Background: Sexual dysfunction is a common disorder among women, especially during menopause. Metabolic syndrome is a multifactorial disease that, according to previous studies, there is a relationshi...
Khoramdad M et al., 2022
Open Access
European Journal of Medical Research
Background: Identifying breast cancer risk factors is a critical component of preventative strategies for this disease. This study aims to identify modifiable and non-modifiable risk factors of breast...
Chang CP et al., 2022Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
Treatment for gynecologic cancer is associated with sexual dysfunction, which may present during and/or after treatment. The aim of this study was to investigate the risk of sexual dysfunction among g...